Qna.files.parliament.uk
Commissioning treatment for dependence on
prescription and over-the-counter medicines:
a guide for NHS and local authority commissioners
What is the issue?
There are distinct but overlapping populations
The 2010 Drug Strategy covers "dependence
using these medicines and they may need dif erent
on al drugs, including prescription and over-the-
counter medicines," and local responses to drug
• Those who use prescription and OTC medicines
misuse and dependence are also expected to cover
as a supplement or alternative to il icit drugs, or
dependence and other problems with medicines
as a commodity to sel
(sometimes cal ed addiction to medicines (ATM) .
• Those who overuse prescription or OTC
medicines to cope with genuine or perceived
(NTA, 2012) suggested that commissioners ask:
physical or psychological symptoms
• "Are innovative responses in place or being
• Those for whom the prescribed use of a
developed to prevent, identify and treat
medicine inadvertently led to dependence,
evidenced and emerging need in relation to
sometimes cal ed involuntary or iatrogenic
addiction to prescribed and over-the-counter
Problems with prescription medicines occur in
And that prescription and over-the-counter (OTC)
the community and in secure environments but
medicines are included in wider considerations of:
the medicines used, populations using them and
• Waiting times for community-based interventions
reasons for misuse or dependence may dif er.
that provide access within three weeks of referral
Health and wel being boards, through their joint
• The treatment system's ability to respond rapidly
strategic needs assessment (JSNA) and joint health
and ef ectively to changing patterns of substance
and wel being strategy, wil want to support health
and public health commissioners to understand local need in relation to addiction to medicines, so
What medicines and who is using them?
that together they can commission appropriate responses. Health commissioners wil likely
Although dependence on prescribed
include both NHS England local teams and clinical
benzodiazepines in the community receives
most media attention, health and public health commissioners wil want to ensure that local y
Understanding local need
appropriate responses are available for problems with a ful range of prescription and OTC medicines,
Commissioners wil want a ful picture of who is
including, but not limited to:
misusing or dependent on what medicines from which sources in order to commission appropriate
• Benzodiazepines and z-drugs, prescribed mainly
local responses.
for anxiety (benzodiazepines only) and insomnia
• Opioid and some other pain medicines, both
Date on prescriptions dispensed in the community
prescribed and bought over-the-counter
is made available to local partnerships via the
• Stimulants, prescribed for ADHD or slimming
prescribing toolkit provided by NHS Prescription Services. There is more information in the NTA's
• Some OTC cough and cold medicines, and anti-
Addiction to medicine report (NTA, 2011) and from
histamines and stimulants.
There is a ful er list at appendix A.
Commissioning treatment for dependence on
prescription and over-the-counter medicines:
a guide for NHS and local authority commissioners
Public health commissioners can ask clinical
Commissioners might also request practice or
commissioning groups (CCGs) for information on the service-based audits of case notes to inform future prescribing patterns of GPs.
Consultation with those af ected by addiction to
– sent to every partnership – includes local NDTMS
medicines or likely to encounter it in their work
data on people in treatment for prescription and OTC is an invaluable source of additional information. medicines, and drug users who have a problem with
Appropriate local consultees might include service
these as wel as il icit drugs (see below).
users (drug & alcohol treatment, mental health),
treatment and other service providers, peer mentors
and volunteers, pharmacy groups, police, probation,
on presenting substance that can be used to
primary and social care staf , tenancy and housing
track changes in the profile of medicines causing
support services, etc.
It has been agreed national y that the
However, NDTMS data only covers those seeking
specialist treatment so may not be most useful for
are not suited to improving benzodiazepine
gaining an understanding of people who do not
approach treatment services or as a source of early intel igence on developing problems with medicines.
What's different about prisons and other secure environments?
Other useful local data sources may include any local ATM and primary-care services that do not
The medicines used, and reasons for their use, in
report to NDTMS.
secure environments general y mirror those in the general population although the scale and nature
Other ways of finding out
may dif er. Prisoners may be more likely than the
general population to suf er from conditions such
monitor, audit and ensure the safe management
as insomnia, anxiety and pain that lead them to
and use of drugs controlled under the Misuse
seek medicines liable to dependence. They may
of Drugs Act. CDAOs in NHS England local
also be more likely to claim these conditions as a
area teams are the accountable officers for their
way of obtaining medicines for personal misuse or
CD local intelligence networks and they have a
as currency. They wil also have less access to OTC
surveillance role over community prescribing and
pharmacies. NHS trusts and independent hospitals
PHE wil publish a guide on managing persistent
are also required to appoint CDAOs. Many of the
pain in secure environments, in June 2013. This will
medicines listed in appendix A are controlled drugs
complement Safer Prescribing in Prisons (RCGP,
so will be considered by accountable officers in
Figure 1: Example of JSNA data
PRESCRIPTION ONLY MEDICINE/OVER THE COUNTER MEDICINE (POM/OTC)
People in treatment for prescription-only medicines (POM) or over the counter medicines (OTC), and drug users who have a problem with these as wel as il icit drugs are presented below. The drug strategy encourages local areas to ensure their services have the capacity to help people get the support that they need for POM and OTC dependence.
Proportion of
Proportion of
Proportion of treatment
treatment
treatment
population citing POM/OTC
Number of adults
citing POM/OTC use
Commissioning treatment for dependence on
prescription and over-the-counter medicines:
a guide for NHS and local authority commissioners
Responding to local need
for co-occurring and emerging mental and physical health problems
PreventionThis guide is concerned with the treatment of
• Where and when interventions should be
problems of dependence that have arisen in people
provided. Patients may be uncomfortable sharing
prescribed certain medicines or buying them.
space with those using il icit drugs and – whether
However, commissioners wil also want to consider
ultimately this should be accepted or chal enged
how problems can be prevented. Primary and
– responses need to focus on engaging and
secondary healthcare, public health and social care
retaining people, which may mean them
can together contribute to:
providing (and commissioners funding) separate ATM sessions, premises or services.
• Ensuring that psychological and other treatments
are available as alternatives to prescribing
These specialist responses may be in existing or
medicines, including through the Increasing
newly-commissioned services that deal with a
Access to Psychological Therapies (IAPT)
range of drug and alcohol issues or they may be
complemented or better provided by separate, dedicated, ATM services and support groups. This
• Ensuring that the public and patients are aware
is necessarily a local decision in response to local
of the problems that can arise with these
need, history and context.
medicines, and understand why their availability may be limited in duration or quantity
This guide is not intended to provide clinical advice on withdrawal from long-term benzodiazepine
• Ensuring that doctors, pharmacists, social care
dependence. However, commissioned treatment
staf and others are aware of current guidance on wil be based on clinical advice, which you can
these medicines and are alert to any developing
read more about in the publications listed in ‘further
problems in patients
reading' below.
• Monitoring and responding to prescribing and
Commissioners wil want to ensure that
commissioned services include appropriate
clinical governance mechanisms to ensure safe
Primary care wil be the first port of cal for most
and ef ective prescribing of medicines liable to
patients dependent on prescription or OTC
dependence and for the treatment of dependence,
and to prevent and detect diversion of prescription medicines by patients.
If patients are not comfortable returning to the GP who prescribed the medicine on which they have
become dependent, they have the right to see
Primary care practices can be expected to respond
another GP or register with another practice.
to ATM problems as part of their regular patient care, within the terms of the General Medical Services
Patients, and sometimes their GPs, may be unaware (GMS) contract.
that there is a problem with a prescription or OTC medicine. ATM outreach services in primary care
Specialist responses wil usual y be commissioned
practices can help to identify problems and link
as part of the drug and alcohol misuse treatment
patients to appropriate treatment.
system, from one or more of the fol owing, as local y appropriate:
Specialist responses can support and advise GPs to provide treatment and to recognise when a
• Primary care (providing an enhanced service)
patient needs more specialist care, and can treat
• A provider of integrated drug and alcohol
patients who cannot be treated in standard primary
treatment services
care. Commissioners wil need to ensure that those providing specialist responses consider:
• A dedicated (often voluntary sector) ATM provider.
• The knowledge and expertise needed to treat
It wil also be important to ensure that pain
patients, some of whom may have been using
management, mental health, and drug and alcohol
medicines for many years and may need long-
treatment services work together and provide
term withdrawal and extensive support, including
coordinated and integrated responses to patients.
Commissioning treatment for dependence on
prescription and over-the-counter medicines:
a guide for NHS and local authority commissioners
Voluntary sector responses – which can range from
consideration of the extent of dependence and
informal support groups to ful y-fledged service
harm. London: National Addiction Centre.
provider organisations – may have arisen and been supported in a number of ways, including:
Further readingThe has published
• From member support and donations
• Fundraising and charitable trust funding
Commissioners wanting to better understand
• Directly commissioned local y:
the clinical issues involved in treating addiction to medicines can refer to the fol owing:
As part of drug treatment by the NHS or
• The contains current
advice on appropriate prescribing and on
As part of mental health treatment by the
NHS or local authority
• Funded as part of local authority support for the
benzodiazepine and z-drug withdrawal provides
voluntary and community sector.
an accessible summary of the evidence base
Commissioners contracting with voluntary sector
and guidance on best practice for primary care
providers wil want to consider and honour
between government and the voluntary
and community sector so that, for instance, services
is principal y concerned
are given multi-year funding where possible.
with the treatment of those dependent on il icit
A checklist for consideration of addiction to
drugs but also covers benzodiazepine misuse
medicines in needs assessment is included as
• The describes a widely-
supported protocol for withdrawal from long-term
References and further reading
• The publishes a
Home Office (2010) – Reducing
on clinical and other pain
Demand, Restricting Supply, Building Recovery:
Supporting People to Live a Free Life. London: Home Office.
A range of guidance covers the use of
medicines for insomnia, anxiety, pain, etc that are
NTA (2011): an investigation
liable to misuse and dependence.
into the configuration and commissioning of treatment services to support those who develop problems with prescription-only or over-the-counter medicine. London: National Treatment Agency for Substance Misuse.
NTA (2012)
of recovery in communities 2013. London: National Treatment Agency for Substance Misuse.
RCGP (2011) London: Royal Col ege of General
Practitioners.
Reed K, Bond A, Witton J, Cornish R, Hickman M & Strang J (2011) The changing use of prescribed benzodiazepines and z-drugs and of over-the-counter codeine-containing products in England: a structured review of published English and international evidence and available data to inform
Commissioning treatment for dependence on
prescription and over-the-counter medicines:
a guide for NHS and local authority commissioners
Appendix A. Some medicines liable to misuse or
Opioid pain medicines
• The proper or generic medicine name is fol owed
• Methadone [Physeptone]
notes or other names, including those used • Oxycodone [OxyNorm]
in medicine combinations, in brackets ()
• Tramadol [Zydol]
example brand names, some no longer
available in UK, in square brackets []
• Codeine (with paracetamol = co-codamol)
• The list does not distinguish between medicines
that are prescription-only or available over-
• Dihydrocodeine (with paracetamol = co-
the-counter without a prescription (either from
dydramol) [Paramol]
pharmacies only or from any shop, often only in limited quantities). For more information, see the
Epilepsy and pain medicines
• Pregabalin (also licensed for anxiety) [Lyrica]
• The remit of this guide is restricted to medicines
with psychoactive properties, as is this list. Other medicines, such as, for example, laxatives and
anabolic steroids, may also be liable to misuse but are not included here.
• Methylphenidate [Ritalin]
• A comprehensive list of medicines recorded in
• Dexamfetamine
the National Drug Treatment Monitoring System
is contained in annex 1 of the NTA's 2011 Addiction to medicine report.
• Caf eine [Pro-plus]
Benzodiazepines and z-drugs
Some cough and cold, anti-diarrhoea, and anti-allergy medicines
• Benzodiazepines
• Opium tincture [Gee's linctus]
• Codeine linctus
Diazepam [Valium]
• Anhydrous morphine [J.Col is Browne's Mixture]
• Kaolin and morphine
Lorazepam [Ativan]
• Sedative antihistamines such as promethazine
Nitrazepam [Mogadon]
[Phenergan] and diphenhydramine [Benadryl,
Some people also report problems withdrawing from antidepressants (e.g. amitriptyline, fluoxetine
[Prozac], paroxetine [Seroxat], venlafaxine [Efexor]),
• Z-drugs (although z-drugs dif er chemical y
and it is general y best to taper of the dose of
from the benzodiazepines, they have the same
an antidepressant rather than stop it suddenly.
However, there is no clear evidence that these medicines can produce dependence according to
Zaleplon [Sonata]
international y accepted criteria.
Zolpidem [Stilnoct]
Zopiclone [Zimovane]
Commissioning treatment for dependence on
prescription and over-the-counter medicines:
a guide for NHS and local authority commissioners
Appendix B. Commissioning for addiction to
medicines: needs assessment checklist
Range of medicines:
• Benzodiazepines and z-drugs – prescribed and
• Clinicians (doctors, pharmacists, nurses, etc and
il icitly obtained
their local groups)
• Opioid and some other pain medicines –
• Current, potential and past service users
prescription, OTC and il icitly obtained
• Control ed drugs accountable officers
• Stimulants, prescribed for ADHD or slimming• Other OTC medicines
Joint work between HWBs and local and national commissioners, specifying their
current and desired provision, etc.
• Prescription and OTC medicines as a
supplement or alternative to il icit drugs, or as a commodity to sel
• Overuse of prescription or OTC medicines to
cope with genuine or perceived physical or psychological symptoms
• Inadvertently dependent fol owing prescribed use
Range of environments:• Community• Hospitals• Secure environments
Existing services/responses:• Primary care• Specialist treatment• Voluntary sector support groups and services
Data sources:• NHS Prescription Services• JSNA support data from NDTMS• Quarterly (Green) NDTMS reports• Local ATM and primary care services
Gateway number: 2013052
Source: http://qna.files.parliament.uk/qna-attachments/454667%5Coriginal%5Cpheatmcommissioningguide.pdf
GREEN MEDICINE: USING LESSONS FROM TORT LAW AND ENVIRONMENTAL LAW TO HOLD PHARMACEUTICAL MANUFACTURERS AND AUTHORIZED DISTRIBUTORS LIABLE FOR INJURIES CAUSED BY COUNTERFEIT DRUGS Stephanie Feldman Aleong* The majority of the American public would be astonished by the frequency with which counterfeit prescription drugs appear on reputable drugstore shelves. In 2004, the Food and Drug Administration (FDA) noted thatthose who counterfeit prescription drugs "deny ill patients the therapies thatcan alleviate suffering and save lives."1 In 2006, the World HealthOrganization (WHO) estimated that there exists a $30 billion market in fakedrugs.2 Although the FDA has tried to characterize the incidence of
Green Tea, the "Asian Paradox,"and Cardiovascular Disease Bauer E Sumpio, MD, PhD, FACS, Alfredo C Cordova, MD, David W Berke-Schlessel, BS, Feng Qin, MD,Quan Hai Chen, MD Archeologic findings have revealed that infusions of 75% to 80%of the 140 million cups of tea consumed leaves from various wild plants, including the tea plant, might have been consumed for more than 500,000